Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States

Amanda M. DiNofia; Elizabeth Salazar; Alix E. Seif; Yimei Li; Yuan Shung Vera Huang; Rochelle Bagatell; Brian T. Fisher; Richard Aplenc

doi:10.1371/journal.pone.0151362

Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States

Amanda M. DiNofia, Elizabeth Salazar, Alix E. Seif, Yimei Li, Yuan Shung Vera Huang, Rochelle Bagatell, Brian T. Fisher, Richard Aplenc

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.

Original language	English
Article number	e0151362
Journal	PLoS ONE
Volume	11
Issue number	3
DOIs	https://doi.org/10.1371/journal.pone.0151362
State	Published - Mar 2016
Externally published	Yes

Access to Document

10.1371/journal.pone.0151362

Cite this

@article{80bbbfa4893d47278c898b59922b89b9,

title = "Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States",

abstract = "This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.",

author = "DiNofia, {Amanda M.} and Elizabeth Salazar and Seif, {Alix E.} and Yimei Li and {Vera Huang}, {Yuan Shung} and Rochelle Bagatell and Fisher, {Brian T.} and Richard Aplenc",

note = "Publisher Copyright: {\textcopyright} 2016 DiNofia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2016",

month = mar,

doi = "10.1371/journal.pone.0151362",

language = "English",

volume = "11",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "3",

}

TY - JOUR

T1 - Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States

AU - DiNofia, Amanda M.

AU - Salazar, Elizabeth

AU - Seif, Alix E.

AU - Li, Yimei

AU - Vera Huang, Yuan Shung

AU - Bagatell, Rochelle

AU - Fisher, Brian T.

AU - Aplenc, Richard

N1 - Publisher Copyright: © 2016 DiNofia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2016/3

Y1 - 2016/3

N2 - This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.

AB - This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.

UR - http://www.scopus.com/inward/record.url?scp=84962263642&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0151362

DO - 10.1371/journal.pone.0151362

M3 - Article

C2 - 26978062

AN - SCOPUS:84962263642

SN - 1932-6203

VL - 11

JO - PLoS ONE

JF - PLoS ONE

IS - 3

M1 - e0151362

ER -

Bortezomib inpatient prescribing practices in free-standing children's hospitals in the United States

Abstract

Access to Document

Fingerprint

Cite this